Coenzyme Q10, Vitamin E and Polyvitamin B: an exploratory double-blind randomized cross-over study in Phelan-McDermid Syndrome

Abstract

Aim: Defective mitochondrial function and increased oxidative stress have been documented in Autism Spectrum Disorder (ASD) and Phelan-McDermid syndrome (PMS), one of the best-known monogenic forms of ASD. The purpose of this exploratory, double-blind, randomized cross-over trial (RCT) is to verify the efficacy and safety of a “metabolic support therapy” (MST) in PMS, while defining the experimental methodology most apt at maximizing sensitivity and reliability.

Methods: A total of 31 PMS patients completed 4 months of Coenzyme Q10 (50/100 mg b.i.d.) + vitamin E (30/60 mg/d) + polyvitamin B ("active compound") vs. 4 months of only Vitamins E and B ("active comparator"). To explore their sensitivity and reliability, four primary outcome measures were used: VABS, CARS, CGI-I, and VAS. Secondary outcome measures span adaptive behaviors, social cognition, autism, problem behaviors, quality of life (QoL), communication, and comorbidities.

Results: CoQ10+vit. E and B yielded significantly greater improvement in several measures of cognition and adaptive functioning, motor skills, and stereotypic behaviors compared to vit. E and B only. Maternal QoL was especially improved in the presence of CoQ10 (P < 0.004). Time x Treatment interactions in CGI-I and VAS "restricted interests" scores support positive contributions also by vitamins E and B. Side effects, including hyperactivity, insomnia, and irritability, were mild, rare, and did not differ between treatment periods.

Conclusion: MST may produce small-to-moderate improvement, especially in motor skills, social motivation, adaptive behaviors, responsiveness to environmental stimulation, and stereotypic behaviors in up to approximately 70% of PMS patients. A targeted confirmatory RCT contrasting Q10+vit E and B vs. inactive placebo is now warranted.

Keywords

22q13 deletion syndrome / autism / autism spectrum disorder / coenzyme Q10 / Phelan-McDermid syndrome / SHANK3 / vitamin B / vitamin E.

References

[1] Phelan MC,Saul RA.22q13 deletion syndrome.Am J Med Genet2001;101:91-9

[2] Phelan K,Boccuto L. Phelan-McDermid syndrome. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle; 2005. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1198/[Last accessed on 10 Jul 2023]

[3] Phelan K.The 22q13.3 deletion syndrome (Phelan-McDermid Syndrome).Mol Syndromol2012;2:186-201 PMCID:PMC3366702

[4] Kolevzon A,Bush L.Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring.J Neurodev Disord2014;6:39 PMCID:PMC4362650

[5] National Organization for Rare Disorders. Phelan-cDermid sndrome. Available from: https://rarediseases.org/rare-diseases/phelan-mcdermid-syndrome/#affected-populations [Last accessed on 7 Jul 2023]

[6] Betancur C.SHANK3 haploinsufficiency: a "common" but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders.Mol Autism2013;4:17. PMCID:PMC3695795

[7] Soorya L,Zweifach J.Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency.Mol Autism2013;4:18 PMCID:PMC3707861

[8] Sarasua SM,Sharp JL.Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome.Hum Genet2014;133:847-59

[9] Kohlenberg TM,McLarney B,Thurm A.Psychiatric illness and regression in individuals with Phelan-McDermid syndrome.J Neurodev Disord2020;12:7 PMCID:PMC7014655

[10] Kolevzon A,Berry-Kravis E,Betancur C.Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature.Mol Autism2019;10:50 PMCID:PMC6930682

[11] De Rubeis S,Durkin A.Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations.Mol Autism2018;9:31 PMCID:PMC5921983

[12] Disciglio V,Mencarelli MA.Interstitial 22q13 deletions not involving SHANK3 gene: a new contiguous gene syndrome.Am J Med Genet A2014;164A:1666-76

[13] Ricciardello A,Persico AM.Genotype-phenotype correlation in Phelan-McDermid syndrome: A comprehensive review of chromosome 22q13 deleted genes.Am J Med Genet A2021;185:2211-33 PMCID:PMC8251815

[14] Vondráčková A,Kratochvílová H.Large copy number variations in combination with point mutations in the TYMP and SCO2 genes found in two patients with mitochondrial disorders.Eur J Hum Genet2014;22:431-4 PMCID:PMC3925276

[15] Frye RE.Mitochondrial disease in 22q13 duplication syndrome.J Child Neurol2012;27:942-9

[16] Costales JL.Phelan-McDermid sndrome and SHANK3: iplications for teatment.Neurotherapeutics2015;12:620-30 PMCID:PMC4489957

[17] Verhoeven WMA,de Leeuw N.A longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan-McDermid syndrome.Eur J Med Genet2020;63:103751

[18] Wang Y.Understanding ubiquinone.Trends Cell Biol2016;26:367-78.

[19] Mantle D.Bioavailability of cenzyme Q(10): an overview of the absorption process and subsequent metabolism.Antioxidants2020;9:386. PMCID:PMC7278738

[20] Weber C,Hłlmer G.The coenzyme Q10 content of the average Danish diet.Int J Vitam Nutr Res1997;67:123-9

[21] Hargreaves IP.Coenzyme Q10 as a therapy for mitochondrial disease.Int J Biochem Cell Biol2014;49:105e111

[22] Matthews RT,Browne S,Beal MF.Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.Proc Natl Acad Sci USA1998;95:8892-7 PMCID:PMC21173

[23] Rötig A,Geromel V.Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency.Lancet2000;356:391-5

[24] Beal MF.Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.J Bioenerg Biomembr2004;36:381-6

[25] Papucci L,Witort E.Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property.J Biol Chem2003;278:28220-8

[26] Kalayci M,Gul S.Effect of coenzyme Q10 on ischemia and neuronal damage in an experimental traumatic brain-injury model in rats.BMC Neuroscience2011;12:75 PMCID:PMC3160960

[27] Kumari S,Milledge GZ,Li H.Ubisol-Q10 prevents glutamate-induced cell death by blocking mitochondrial fragmentation and permeability transition pore opening.Int J Biol Sci2016; 12:688-700. PMCID:PMC4870712

[28] Degenhardt F,Szymczak S.Genome-wide association study of serum coenzyme Q10 levels identifies susceptibility loci linked to neuronal diseases.Hum Mol Genet2016;25:2881-91

[29] Somayajulu M,Hung M,Borowy-Borowski H.Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10.Neurobiol Dis2005;18:618-27

[30] Moon Y,Park JH,Kim K.Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10.J Neurochem2005;93:1199-208

[31] Hochberg J.Latissimus dorsi myocutaneous flap to restore elbow flexion and axillary burn contracture: a report on two pediatric patients.J Pediatr Orthop1982;2:565-8

[32] Müller T,Gholipour AF.Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.Neurosci Lett2003;341:201-4

[33] Shults CW,Fontaine D,Haas RH.Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients.Neurology1998;50:793-5

[34] Cooper O,Andrabi S.Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.Sci Transl Med2012;4:141ra90 PMCID:PMC3462009

[35] Cucinotta F,Turriziani L.Efficacy and safety of Q10 ubiquinol with vitamins b and e in neurodevelopmental disorders: a retrospective chart review.Front Psychiatry2022;13:829516 PMCID:PMC8927903

[36] Psychiatric Association. Diagnostic and statistical manual of mental disorders.Med Health Care Phil2014;17:241-244.

[37] Soorya L,Trelles MP.Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome.Clin Neuropsychol2018;32:1226-55 PMCID:PMC6417924

[38] Braconnier ML.Neuropsychological assessment in autism spectrum disorder.Curr Psychiatry Rep2021;23:63 PMCID:PMC8324442

[39] Jacquemont S,Hagerman R.The challenges of clinical trials in fragile X syndrome.Psychopharmacology2014;231:1237-50 PMCID:PMC3932172

[40] Sparrow SS,Balla DA. Vineland adaptive behavior scales: second edition (Vineland II), survey interview form/caregiver rating form. Livonia, MN: Pearson Assessments; 2005. Available from: https://www.walmart.com/ip/Vineland-II-Vineland-Adaptive-Behavior-Scales-Survey-Forms-Manual-Interview-Form-Parent-Caregiver-Rating-Form-Pre-Owned-Unknown-Binding-B001P673SK-Do/702415787 [Last accessed on 7 Jul 2023]

[41] Vaughan CA.Test Review: E. Schopler, M. E. Van Bourgondien, G. J. Wellman, & S. R. Love Childhood Autism Rating Scale (2nd ed.). Los Angeles, CA: Western Psychological Services, 2010..J Psychoeduc Assess2011;29:489-93

[42] Guy W. Clinical global impressions ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute for Mental Health; 1976. Available from: https://ia600306.us.archive.org/35/items/ecdeuassessmentm1933guyw/ecdeuassessmentm1933guyw.pdf [Last accessed on 7 Jul 2023]

[43] Guyatt GH,Berman LB.A comparison of likert and visual analogue scales for measuring change in function.J Chronic Dis1987;40:1129-33

[44] Jaeschke R,Guyatt GH.A comparison of seven-point and visual analogue scales. Data from a randomized trial.Control Clin Trials1990;11:43-51

[45] Shaffer D,Brasic J.A children's global assessment scale (CGAS).Arch Gen Psychiatry1983;40:1228-31

[46] Constantino JN,Todd RD.Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised.J Autism Dev Disord2003;33:427-33

[47] Lam KS. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders.J Autism Dev Disord2007;37:855-66

[48] Aman MG,Stewart AW.The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.Am J Ment Defic1985;89:485-91. PMID: 3993694

[49] Tomchek SD.Sensory processing in children with and without autism: a comparative study using the short sensory profile.Am J Occup Ther2007;61:190-200

[50] Conners CK,Parker JD.The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity.J Abnorm Child Psychol1998;26:257-68

[51] Achenbach TM. Manual for the ASEBA preschool forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2000. Available from: https://www.researchgate.net/publication/243771256_Manual_for_the_ASEBA_Preschool_forms_profiles [Last accessed on 7 Jul 2023]

[52] Achenbach TM. Manual for the ASEBA school-age forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2001. Available from: https://store.aseba.org/MANUAL-FOR-THE-ASEBA-SCHOOL-AGE-FORMS-PROFILES/productinfo/505/ [Last accessed on 7 Jul2023]

[53] McConachie H,Parr JR,Wilson C.Enhancing the validity of a quality of life measure for autistic people.J Autism Dev Disord2018;48:1596-611 PMCID:PMC5889785

[54] The WHOQOL GroupDevelopment of the World Health Organization WHOQOL-BREF quality of life assessment.Psychol Med1998;28:551-8

[55] R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Wien, Austria; 2020.

[56] Ponson L,Blanc R.22q13 deletion syndrome: communication disorder or autism?.Transl Psychiatry2018;8:146 PMCID:PMC6082846

[57] Kann O.Mitochondria and neuronal activity.Am J Physiol Cell Physiol2007;292:C641-57

[58] Cheng A,Mattson MP.Mitochondria and neuroplasticity.ASN Neuro2010;2:e00045 PMCID:PMC2949087

[59] Carmeli E,Bachar A.Inflammation and oxidative stress as biomarkers of premature aging in persons with intellectual disability.Res Dev Disabil2012;33:369-75

[60] Valenti D,De Filippis B,Vacca RA.Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome.Neurosci Biobehav Rev2014;46 Pt 2:202-17

[61] Alvarez-Mora MI,Madrigal I,Garrabou G.Impaired mitochondrial function and dynamics in the pathogenesis of FXTAS.Mol Neurobiol2017;54:6896-902

[62] Liu J,Zhan S,Wang L.Coenzyme Q10 for Parkinson's disease. cochrane database of systematic reviews.1996;

[63] Persico AM,Ricciardello A.Autisms. Neurodevelopmental disorders. Elsevier; 2020. pp. 35-77.

[64] Rossignol DA.Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism.Front Physiol2014; 5:150. PMCID:PMC4001006

[65] Palmieri L.Mitochondrial dysfunction in autism spectrum disorders: cause or effect?.Biochim Biophys Acta2010; 1797:1130-7

[66] Palmieri L,Porcelli V.Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1.Mol Psychiatry2010; 15:38-52.

[67] Chauhan A,Chauhan V.Brain region-specific glutathione redox imbalance in autism.Neurochem Res2012; 37:1681-9.

[68] Rose S,Pavliv O.Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain.Transl Psychiatry2012; 2:e134. PMCID:PMC3410618

[69] Frustaci A,Cesario A.Oxidative stress-related biomarkers in autism: systematic review and meta-analyses.Free Radic Biol Med2012; 52:2128-41.

[70] Tang G,Kuo SH.Mitochondrial abnormalities in temporal lobe of autistic brain.Neurobiol Dis2013; 54:349-61 PMCID:PMC3959772

[71] Gu F,Chauhan A.Impaired synthesis and antioxidant defense of glutathione in the cerebellum of autistic subjects: alterations in the activities and protein expression of glutathione-related enzymes.Free Radic Biol Med2013; 65:488-96.

[72] El-Ansary A,Chirumbolo S.Predictive value of selected biomarkers related to metabolism and oxidative stress in children with autism spectrum disorder.Metab Brain Dis2017; 32:1209-21.

[73] Yenkoyan K,Harutyunyan A.A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders.Free Radic Biol Med2018; 123:85-95.

[74] Adams JB,Geis E.The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels.J Toxicol2009; 2009:532640. PMCID:PMC2809421

[75] Ghezzo A,Abruzzo PM.Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features.PLoS One2013;8:e66418 PMCID:PMC3686873

[76] Gorrindo P,Lee EB,Levitt P.Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction.PLoS One2013;8:e68444 PMCID:PMC3700867

[77] Rose S,Murray KF,Winter H.Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: a blinded case-control study.PLoS One2017;12:e0186377. PMCID:PMC5640251

[78] McElhanon BO,Karpen S.Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis.Pediatrics2014;133:872-83.

[79] Frye RE,Slattery J.Mitochondrial dysfunction may explain symptom variation in phelan-mcdermid syndrome.Sci Rep2016;6:19544 PMCID:PMC4731780

[80] Naviaux RK.Oxidative shielding or oxidative stress?.J Pharmacol Exp Ther2012;342:608-18

[81] Adams JB.Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder.J Altern Complement Med2004;10:1033-9

[82] Adams JB,McDonough-Means S.Effect of a vitamin/mineral supplement on children and adults with autism.BMC Pediatr2011;11:111. PMCID:PMC3266205

[83] Adams JB,Geis E.Comprehensive nutritional and dietary intervention for autism spectrum disorder-a randomized, controlled 12-month trial.Nutrients2018;10:369 PMCID:PMC6566397

[84] Dolske MC,McKay S,Tolbert L.A preliminary trial of ascorbic acid as supplemental therapy for autism.Prog Neuropsych Biol Psychiatry1993;17:765-74

[85] Adams JB,Audhya T.Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements.J Altern Complement Med2006;12:59-63

[86] Mousavinejad E,Riahi F,Tiznobeyk Z.Coenzyme Q(10) supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders.Psychiatry Res2018;265:62-9

[87] Eldridge SM,Campbell MJ.PAFS consensus groupCONSORT 2010 statement: extension to randomised pilot and feasibility trials.Pilot Feasibility Stud2016;2:64 PMCID:PMC5154046

[88] Matuleviciene A,Kuiper E.European Phelan-McDermid syndrome guideline consortiumConsensus recommendations on chewing, swallowing and gastrointestinal problems in Phelan-McDermid syndrome.Eur J Med Genet2023;66:104763

[89] Serrada-Tejeda S,Máximo-Bocanegra N,Pérez-de-Heredia-Torres M.Descriptive analysis of adaptive behavior in Phelan-McDermid syndrome and autism spectrum disorder.Front Neurosci2022;16:893003 PMCID:PMC9295709

[90] Droogmans G,Van Buggenhout G.Stressed parents, happy parents. An assessment of parenting stress and family quality of life in families with a child with Phelan-McDermid syndrome.J Appl Res Intellect Disabil2021;34:1076-88.

[91] Jacob S,Hollander E.Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.Mol Autism2022;13:25 PMCID:PMC9188723